Geranylgeranylacetone protects against morphine-induced hepatic and renal damage in mice

Molecular Medicine Reports

Volumn 7, Issue 2, 2013, Pages 694-700

  Luo, Fu Cheng ^a   Zhao, Lu ^a   Deng, Juan ^a   Liang, Min ^a   Zeng, Xian Si ^a   Liu, Hua ^b   Bai, Jie ^a  

^a KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b First People's Hospital of Yunnan Province   (China)

Author keywords

Geranylgeranylacetone; Heat shock protein 70; Kidney; Liver; Morphine; Thioredoxin 1

Indexed keywords

CASPASE 3; CASPASE 9; HEAT SHOCK PROTEIN 70; MALONALDEHYDE; MORPHINE; TEPRENONE; THIOREDOXIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED DISEASE; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; KIDNEY INJURY; LIVER INJURY; MITOCHONDRION; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT DURATION;

ANIMALS; APOPTOSIS; CASPASE 3; CASPASE 9; DITERPENES; HSP70 HEAT-SHOCK PROTEINS; KIDNEY; LIPID PEROXIDATION; LIVER; MALONDIALDEHYDE; MICE; MICE, INBRED C57BL; MITOCHONDRIA; MORPHINE; PROTECTIVE AGENTS; THIOREDOXINS;

EID: 84873829918     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1217     Document Type: Article

References (64)

1. Christie MJ: Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol 154: 384-396, 2008.
2. Weller IV, Cohn D, Sierralta A, et al: Clinical, biochemical, serological, histological and ultrastructural features of liver disease in drug abusers. Gut 25: 417-423, 1984.
3. Colombo JP and Colombo J: Plasma gamma-glutamyl transpeptidase in heroin addicts. Clin Chim Acta 95: 483-486, 1979.
4. May B and Helmstaedt D: Liver disease in drug addicts: clinical course-toxicological and clinical pharmacological aspects. Int J Clin Pharmacol Biopharm 12: 50-56, 1975.
5. Cunningham EE, Brentjens JR, Zielezny MA, Andres GA and Venuto RC: Heroin nephropathy. A clinicopathologic and epidemiologic study. Am J Med 68: 47-53, 1980.
6. Connolly JO, Gillmore JD, Lachmann HJ, Davenport A, Hawkins PN and Woolfson RG: Renal amyloidosis in intravenous drug users. QJM 99: 737-742, 2006.
7. Dettmeyer R, Wessling B and Madea B: Heroin associated nephropathy - a post-mortem study. Forensic Sci Int 95: 109-116, 1998.
8. Bakir AA and Dunea G: Drugs of abuse and renal disease. Curr Opin Nephrol Hypertens 5: 122-126, 1996.
9. Jaffe JA and Kimmel PL: Chronic nephropathies of cocaine and heroin abuse: a critical review. Clin J Am Soc Nephrol 1: 655-667, 2006.
10. Payabvash S, Beheshtian A, Salmasi AH, et al: Chronic morphine treatment induces oxidant and apoptotic damage in the mice liver. Life Sci 79: 972-980, 2006.
11. Panchenko LF, Pirozhkov SV, Nadezhdin AV, Baronets Vlu and Usmanova NN: Lipid peroxidation, peroxyl radical-scavenging system of plasma and liver and heart pathology in adolescence heroin users. Vopr Med Khim 45: 501-506, 1999 (In Russian).
12. Sumathi T and Niranjali Devaraj S: Effect of Bacopa monniera on liver and kidney toxicity in chronic use of opioids. Phytomedicine 16: 897-903, 2009.
13. Atici S, Cinel I, Cinel L, Doruk N, Eskandari G and Oral U: Liver and kidney toxicity in chronic use of opioids: an experimental long term treatment model. J Biosci 30: 245-252, 2005.
14. Zhang YT, Zheng QS, Pan J and Zheng RL: Oxidative damage of biomolecules in mouse liver induced by morphine and protected by antioxidants. Basic Clin Pharmacol Toxicol 95: 53-58, 2004.
15. Burke-Gaffney A, Callister ME and Nakamura H: Thioredoxin: friend or foe in human disease? Trends Pharmacol Sci 26: 398-404, 2005.
16. Lillig CH and Holmgren A: Thioredoxin and related molecules - from biology to health and disease. Antioxid Redox Signal 9: 25-47, 2007.
17. Chae HZ, Chung SJ and Rhee SG: Thioredoxin-dependent peroxide reductase from yeast. J Biol Chem 269: 27670-27678, 1994.
18. Das KC and Das CK: Thioredoxin, a singlet oxygen quencher and hydroxyl radical scavenger: redox independent functions. Biochem Biophys Res Commun 277: 443-447, 2000.
19. Nakamura H, Matsuda M, Furuke K, et al: Adult T cell leukemia-derived factor/human thioredoxin protects endothelial F-2 cell injury caused by activated neutrophils or hydrogen peroxide. Immunol Lett 42: 75-80, 1994.
20. Takagi Y, Mitsui A, Nishiyama A, et al: Overexpression of thioredoxin in transgenic mice attenuates focal ischemic brain damage. Proc Natl Acad Sci USA 96: 4131-4136, 1999.
21. Evans CG, Chang L and Gestwicki JE: Heat shock protein 70 (hsp70) as an emerging drug target. J Med Chem 53: 4585-4602, 2010.
22. Bai J, Nakamura H, Hattori I, Tanito M and Yodoi J: Thioredoxin suppresses 1-methyl-4-phenylpyridinium-induced neurotoxicity in rat PC12 cells. Neurosci Lett 321: 81-84, 2002.
23. Dekigai H, Nakamura H, Bai J, et al: Geranylgeranylacetone promotes induction and secretion of thioredoxin in gastric mucosal cells and peripheral blood lymphocytes. Free Radic Res 35: 23-30, 2001.
24. Fudaba Y, Ohdan H, Tashiro H, et al: Geranylgeranylacetone, a heat shock protein inducer, prevents primary graft nonfunction in rat liver transplantation. Transplantation 72: 184-189, 2001.
25. Yamagami K, Yamamoto Y, Ishikawa Y, Yonezawa K, Toyokuni S and Yamaoka Y: Effects of geranyl-geranyl-acetone administration before heat shock preconditioning for conferring tolerance against ischemia-reperfusion injury in rat livers. J Lab Clin Med 135: 465-475, 2000.
26. Ooie T, Takahashi N, Saikawa T, et al: Single oral dose of geranylgeranylacetone induces heat-shock protein 72 and renders protection against ischemia/reperfusion injury in rat heart. Circulation 104: 1837-1843, 2001.
27. Fujiki M, Kobayashi H, Abe T and Ishii K: Astroglial activation accompanies heat shock protein upregulation in rat brain following single oral dose of geranylgeranylacetone. Brain Res 991: 254-257, 2003.
28. Yamanaka K, Takahashi N, Ooie T, Kaneda K, Yoshimatsu H and Saikawa T: Role of protein kinase C in geranylgeranylacetone-induced expression of heat-shock protein 72 and cardioprotection in the rat heart. J Mol Cell Cardiol 35: 785-794, 2003.
29. Luo FC, Qi L, Lv T, et al: Geranylgeranylacetone protects mice against morphine-induced hyperlocomotion, rewarding effect, and withdrawal syndrome. Free Radic Biol Med 52: 1218-1227, 2012.
30. Mao H, Li Z, Zhou Y, et al: HSP72 attenuates renal tubular cell apoptosis and interstitial fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol 295: F202-F214, 2008.
31. Fudaba Y, Tashiro H, Miyata Y, et al: Oral administration of geranylgeranylacetone protects rat livers from warm ischemic injury. Transplant Proc 31: 2918-2919, 1999.
32. Ikeyama S, Kusumoto K, Miyake H, Rokutan K and Tashiro S: A non-toxic heat shock protein 70 inducer, geranylgeranylacetone, suppresses apoptosis of cultured rat hepatocytes caused by hydrogen peroxide and ethanol. J Hepatol 35: 53-61, 2001.
33. Nishida T, Matsura T, Nakada J, et al: Geranylgeranylacetone protects against acetaminophen-induced hepatotoxicity by inducing heat shock protein 70. Toxicology 219: 187-196, 2006.
34. Kanemura H, Kusumoto K, Miyake H, Tashiro S, Rokutan K and Shimada M: Geranylgeranylacetone prevents acute liver damage after massive hepatectomy in rats through suppression of a CXC chemokine GRO1 and induction of heat shock proteins. J Gastrointest Surg 13: 66-73, 2009.
35. Suzuki S, Maruyama S, Sato W, et al: Geranylgeranylacetone ameliorates ischemic acute renal failure via induction of Hsp70. Kidney Int 67: 2210-2220, 2005.
36. Katsuno M, Sang C, Adachi H, et al: Pharmacological induction of heat-shock proteins alleviates polyglutamine-mediated motor neuron disease. Proc Natl Acad Sci USA 102: 16801-16806, 2005.
37. Ooie T, Kajimoto M, Takahashi N, et al: Effects of insulin resistance on geranylgeranylacetone-induced expression of heat shock protein 72 and cardioprotection in high-fat diet rats. Life Sci 77: 869-881, 2005.
38. Kim YH, Song JJ, Kim YC, et al: Geranylgeranylacetone ameliorates acute cochlear damage caused by 3-nitropropionic acid. Neurotoxicology 31: 317-325, 2010.
39. Zhang K, Zhao T, Huang X, et al: Preinduction of HSP70 promotes hypoxic tolerance and facilitates acclimatization to acute hypobaric hypoxia in mouse brain. Cell Stress Chaperones 14: 407-415, 2009.
40. Hassanzadeh K, Roshangar L, Habibi-asl B, et al: Riluzole prevents morphine-induced apoptosis in rat cerebral cortex. Pharmacol Rep 63: 697-707, 2011.
41. Hassanzadeh K, Habibi-asl B, Farajnia S and Roshangar L: Minocycline prevents morphine-induced apoptosis in rat cerebral cortex and lumbar spinal cord: a possible mechanism for attenuating morphine tolerance. Neurotox Res 19: 649-659, 2011.
42. Crowe AV, Howse M, Bell GM and Henry JA: Substance abuse and the kidney. QJM 93: 147-152, 2000.
43. Singhal PC, Sharma P, Sanwal V, et al: Morphine modulates proliferation of kidney fibroblasts. Kidney Int 53: 350-357, 1998.
44. Singhal PC, Gibbons N and Abramovici M: Long term effects of morphine on mesangial cell proliferation and matrix synthesis. Kidney Int 41: 1560-1570, 1992.
45. Patel J, Manjappa N, Bhat R, Mehrotra P, Bhaskaran M and Singhal PC: Role of oxidative stress and heme oxygenase activity in morphine-induced glomerular epithelial cell growth. Am J Physiol Renal Physiol 285: F861-F869, 2003.
46. Pan J, Zhang Q, Zhang Y, Ouyang Z, Zheng Q and Zheng R: Oxidative stress in heroin administered mice and natural antioxidants protection. Life Sci 77: 183-193, 2005.
47. Singhal PC, Bhaskaran M, Patel J, et al: Role of p38 mitogen activated protein kinase phosphorylation and Fas-Fas ligand interaction in morphine-induced macrophage apoptosis. J Immunol 168: 4025-4033, 2002.
48. Khanna N and Singh N: Role of caspases in apoptosis and disease. Indian J Physiol Pharmacol 43: 151-159, 1999.
49. Friedlander RM: Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 348: 1365-1375, 2003.
50. Hassanzadeh K, Habibi-asl B, Roshangar L, Nemati M, Ansarin M and Farajnia S: Intracerebroventricular administration of riluzole prevents morphine-induced apoptosis in the lumbar region of the rat spinal cord. Pharmacol Rep 62: 664-673, 2010.
51. Fujita E, Kouroku Y, Jimbo A, Isoai A, Maruyama K and Momoi T: Caspase-12 processing and fragment translocation into nuclei of tunicamycin-treated cells. Cell Death Differ 9: 1108-1114, 2002.
52. Nakagawa T, Zhu H, Morishima N, et al: Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-beta. Nature 403: 98-103, 2000.
53. Calabrese V, Cornelius C, Mancuso C, et al: Vitagenes, dietary antioxidants and neuroprotection in neurodegenerative diseases. Front Biosci 14: 376-397, 2009.
54. Masutani H, Bai J, Kim YC and Yodoi J: Thioredoxin as a neurotrophic cofactor and an important regulator of neuroprotection. Mol Neurobiol 29: 229-242, 2004.
55. Ammon S, Mayer P, Riechert U, Tischmeyer H and Hollt V: Microarray analysis of genes expressed in the frontal cortex of rats chronically treated with morphine and after naloxone precipitated withdrawal. Brain Res Mol Brain Res 112: 113-125, 2003.
56. Rodriguez Parkitna JM, Bilecki W, Mierzejewski P, et al: Effects of morphine on gene expression in the rat amygdala. J Neurochem 91: 38-48, 2004.
57. Hoshino Y, Nakamura T, Sato A, Mishima M, Yodoi J and Nakamura H: Neurotropin demonstrates cytoprotective effects in lung cells through the induction of thioredoxin-1. Am J Respir Cell Mol Biol 37: 438-446, 2007.
58. Tanito M, Kwon YW, Kondo N, et al: Cytoprotective effects of geranylgeranylacetone against retinal photooxidative damage. J Neurosci 25: 2396-2404, 2005.
59. Tanito M, Masutani H, Kim YC, Nishikawa M, Ohira A and Yodoi J: Sulforaphane induces thioredoxin through the antioxidant-responsive element and attenuates retinal light damage in mice. Invest Ophthalmol Vis Sci 46: 979-987, 2005.
60. Luo FC, Wang SD, Li K, Nakamura H, Yodoi J and Bai J: Panaxatriol saponins extracted from Panax notoginseng induces thioredoxin-1 and prevents 1-methyl-4-phenylpyridinium ion-induced neurotoxicity. J Ethnopharmacol 127: 419-423, 2010.
61. Hashimoto S, Matsumoto K, Gon Y, et al: Thioredoxin negatively regulates p38 MAP kinase activation and IL-6 production by tumor necrosis factor-alpha. Biochem Biophys Res Commun 258: 443-447, 1999.
62. Saitoh M, Nishitoh H, Fujii M, et al: Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J 17: 2596-2606, 1998.
63. Guo S, Wharton W, Moseley P and Shi H: Heat shock protein 70 regulates cellular redox status by modulating glutathione-related enzyme activities. Cell Stress Chaperones 12: 245-254, 2007.
64. Hirota K, Nakamura H, Arai T, et al: Geranylgeranylacetone enhances expression of thioredoxin and suppresses ethanol-induced cytotoxicity in cultured hepatocytes. Biochem Biophys Res Commun 275: 825-830, 2000.